


DU Balance Hormone Profile

Comments:




Estrogens


Reference Ranges

Postmenopausal women on hormones, or cycling women collecting during the luteal phase, refer to the luteal reference range.

Postmenopausal women not taking hormones, refer to the postmenopausal reference range



Phase I Metabolites



Phase II Metabolites



Other Reference Ranges

	Estrone	Estradiol	Estriol	Estrogen Total	Pregnanediol
Follicular	2.0-39	1.0-23	3.0-48	7.0-110	0-2500
Mid-Cycle	11.0-46	4.0-45	20-130	38-221	N/A



DU Balance Hormone Profile

Accession #:

Test Code: 4990


Patient Name:

Estrogen Ratios

Estrogen Ratios


Estrogen Quotient: 3.8
E3/(E1+E2)

Patient Result



Reference Range


>1




Patients with an EQ>1 have a higher survival rate after breast cancer, and may be at decreased risk for developing breast cancer. EQ often declines as women enter menopause.

Estrogen Hydroxylation

Patient Result



Reference Range



2-OHE1, a Phase I liver metabolite of estrone, is considered protective. 16α-OHE1 is a Phase I metabolite of estrone that has some duality: it is potentially carcinogenic and it is important for building bone. Therefore, very high levels and very low levels are both undesirable. High levels suggest a need for measures to improve estrogen detoxification. Low levels may increase risk of osteopenia.

4-OHE1 is a highly carcinogenic Phase I metabolite. Low levels are desirable.

Methylation Ratio: 0.28
2-Methoxyestrone/2OHE1

Patient Result



Reference Range

0.2 - 0.65



A comparison of 2-Methoxyestrone with 2OHE1 allows insight into methylation pathways. If the methylation ratio is on the low end of the reference range, consider adding supplements to improve methylation. If needed, consider further testing for methylation defects.

Progesterone

µg/g Creatinine

Reference Ranges

5β-Pregnanediol

137 L




DU Balance Hormone Profile

Accession #:


Test Code: 4990

Patient Name:


Androgens



Glucocorticoids



Mineralocorticoids



DU Balance Hormone Profile

Accession #:

Test Code: 4990


Patient Name:

Enzyme Activity Phenotype Assessment

5 α -Reductase

Andro/Etio Ratio

0.71



5 α -THF/THF Ratio

0.48

L



Elevated 5 α -reductase activity is associated with Polycystic Ovarian Syndrome (PCOS) and hirsutism in women, Benign Prostatic Hyperplasia (BPH) and premature baldness in men, and obesity and insulin resistance in both genders. Low 5 α -reductase activity may result in reduced conversion of testosterone to DHT and undervirilization in males.

11 β -HSD II (11 β -hydroxysteroid dehydrogenase II)

Cortisol/Cortisone Ratio (11 β -HSD II)

0.77



11 β -HSD II is predominantly a renal enzyme. It inactivates cortisol in order to prevent competitive binding to mineralocorticoid receptors. Its activity can be measured by the ratio of cortisol/cortisone. An elevated ratio (toward right on the graph) indicates suppressed enzyme activity, and may be clinically related to stress, hypertension, high dose licorice, cortisol administration, or insulin resistance.

Other Analytes

Melatonin

$\mu\text{g/g}$ Creatinine

Reference Range

6-Sulfatoxymelatonin (1st Morning)

62.2



Thyroid

$\mu\text{g/g}$ Creatinine

Reference Range

Free T3

339



Free T4

630



Organic Acids

mg/g Creatinine

Reference Range

Kynurenic

0.93



Xanthurenic

0.33



DU Balance Hormone Profile


Accession #:

Test Code: 4990


Patient Name:

4-Point Cortisol and Cortisone


Cortisol	µg/g	Range
1st Morning	23.1	4.4 - 26.9
2nd Morning	14.6 L	15.5 - 108
Afternoon	7.1	6.2 - 26.7
Night	3.1	1.8 - 17.7



Cortisone	µg/g	Range
1st Morning	55.9	18.2 - 69.3
2nd Morning	61.3	41 - 177.1
Afternoon	45.7	28.4 - 101.3
Night	23.3	10.3 - 58.8



Creatinine	mg/dL	Range
1st Morning	108	35 - 270
2nd Morning	117	35 - 270
Afternoon	110	35 - 270
Night	58	35 - 270



----- Upper and lower limits of reference range.

